Overview of X-FORCE
Quick Facts
| Property | Description |
|---|---|
| Active Ingredient | Sildenafil (as Sildenafil Citrate) |
| Form | Oral tablet (typically film-coated) |
| Pharmacological Class | Selective Phosphodiesterase type 5 (PDE5) Inhibitor |
| General Purpose | Enhancing localized blood flow |
| Origin | Synthetic compound |
What Type of Medicine is X-FORCE?
X-FORCE is a synthetic pharmaceutical preparation whose active component is Sildenafil Citrate. It is classified as a highly selective Phosphodiesterase type 5 (PDE5) inhibitor. This categorization places the drug within a specific class of compounds designed to modulate the vascular system, an action utilized for circulatory-related management. Sildenafil, as a PDE5 inhibitor, acts on the cGMP-specific phosphodiesterase type 5 enzyme. This means the medicine works by specifically targeting a single enzyme to achieve its therapeutic effect.
As a member of the PDE5 inhibitor class, X-FORCE is a highly targeted compound. Its origin is a synthetic pyrazolo-pyrimidinone derivative, which means it is manufactured via chemical synthesis rather than being derived from natural sources. This structure ensures a consistent and predictable pharmacological profile.
The Composition and Form of X-FORCE
The core active ingredient in X-FORCE is Sildenafil, which is administered as the salt, Sildenafil Citrate. The medication is delivered in the form of an oral tablet for ease of systemic administration, a feature distinguishing it from non-oral or localized treatments.
The choice to use Sildenafil Citrate facilitates the effective delivery of the active compound following the oral route of administration. The tablet consists of the active ingredient integrated into a stable, solid pharmaceutical excipient matrix, ensuring a precise and standardized dose for adult patients requiring systemic vascular support.
X-FORCE's General Purpose and Action
The general purpose of X-FORCE is to utilize its selective enzyme inhibition to promote vasodilation, facilitating enhanced blood flow. Selective PDE5 inhibitors primarily induce vasodilation. This confirms the drug's fundamental job is to help widen blood vessels to improve circulation.
The ability of this medication to temporarily block the PDE5 enzyme leads directly to the enhanced effects of nitric oxide (NO), promoting the necessary relaxation of smooth muscles in blood vessel walls. This targeted vasodilation provides the foundational physiological action for the drug’s general utility, supporting a typical use scenario where improved localized blood flow is crucial for function.
Regulatory References
